Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial.
Kawakami H, Sunakawa Y, Inoue E, Matoba R, Noda K, Sato T, Suminaka C, Yamaki M, Sakamoto Y, Kawabata R, Ishiguro A, Akamaru Y, Kito Y, Yabusaki H, Matsuyama J, Takahashi M, Makiyama A, Hayashi H, Chamoto K, Honjo T, Nakagawa K, Ichikawa W, Fujii M.
Kawakami H, et al. Among authors: ichikawa w.
Eur J Cancer. 2023 May;184:10-20. doi: 10.1016/j.ejca.2023.02.003. Epub 2023 Feb 10.
Eur J Cancer. 2023.
PMID: 36889037